Pharminox promotes Dr Marc Hummersone

pharmafile | August 12, 2010 | Appointment | Research and Development Pharminox, appointment, research and development 

Nottingham, UK-based cancer drug discovery and development company Pharminox has appointed Dr Marc Hummersone as research director.

Marc first joined the company from KuDOS Pharmaceuticals in April 2008 as head of chemistry, and in his new role , will take on full responsibility for discovery research operations and strategy within Pharminox.

Meanwhile, Professor Malcolm Stevens is standing down from the board and as chief scientific officer (CSO) and will take up the honorary position of CSO Emeritus

Peter Worrall, chief executive of Pharminox said: “Marc’s appointment recognises the exceptional contribution that he has made in the two years since he came to Pharminox, both in building a high calibre discovery research team and also in refining the Company’s discovery activities to focus on targeted DNA damage and inhibition of DNA repair.

“I would also like to take this opportunity to thank Malcolm Stevens for the huge contribution he has made to the development of Pharminox over the last six years. I am very pleased that Malcolm intends to retain close ties with the Company in his new role as CSO Emeritus, and that we will continue to benefit from his valuable insights and enormous experience in cancer drug discovery.” 

Related Content

sarah_mcdonald

Myeloma UK reveals new Director of Research appointment

UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …

white_and_ford

Abbott CEO to step down after 21 years

After more than two decades at the head of the company, it has emerged that …

funk

Lonza CEO to step down in 2020

It has been announced that Marc Funk, Chief Executive Officer at Lonza, is set to …

Latest content